Investigator Sanjit S. Jolly, MD, MSc, FRCPC summarizes the results of the ACT Outpatient and ACT Inpatient trials, which looked at whether anti-inflammatory and anti-coagulation therapies showed benefit for patients diagnosed with COVID-19 in outpatient and inpatient settings respectively.